Actively Recruiting Prostate Cancer Clinical Trials Summary

By Class of Drug

I Non-Steroidal Anti Androgen

These drugs work by preventing the active form of testosterone (also known as DHT) from stimulating the prostate and prostate cancer cells to grow.

ENACT

o Study Drug: enzalutamide (Xtandi)

o Sponsor: Astellas Pharma

o Phase 2

o PHEN Information

o Clinicaltrials.gov Information

ARASENS

o Study Drug: darolutamide

o Sponsor: Bayer

o Phase 3

o PHEN Information

o Clinicaltrials.gov Information

EMBARK

o Study Drug: enzalutamide (Xtandi)

o Sponsor: Pfizer

o Phase 3

o PHEN Information

o Clinicaltrials.gov Information

ATLAS

o Study Drug: apalutamide (Erleada)

o Sponsor: Aragon Pharmaceuticals

o Phase 3

o Clinicaltrials.gov Information

PANTHER

o Study Drugs: apalutamide (Erleada) & abiraterone (Zytiga)

o Sponsor: Janssen Scientific

o Phase 2

o Clinicaltrials.gov Information

CYPIDES

o Study Drug: ODM-208

o Sponsor: Orion Pharma

o Phase 2

o Clinicaltrials.gov Information

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

o Study Drug: proxalutamide

o Sponsor: Suzhou Kintor Pharma

o Phase 2

o Clinicaltrials.gov Information

II GNRH Antagonist

This class of drugs prevents the release of certain hormones that stimulate testosterone production in the body. The decrease in testosterone productions leads to less prostate and prostate cancer cell stimulation. 

HERO

o Study Drug: relugolix

o Sponsor: Myovant Sciences GmbH

o Phase 3

o Clinicaltrials.gov Information

PRONOUNCE

o Study Drug: degarelix (Firmagon)

o Sponsor: Ferring Pharmaceuticals

o Phase 3

o Clinicaltrials.gov Information

III GNRH Agonist

This class of drugs prevents male testosterone production by blocking other hormones involved in making them. The decrease in testosterone productions leads to less prostate and prostate cancer cell stimulation. 

An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects With Prostate Cancer

o Study Drug: Leuprolide Mesylate

o Sponsor: Foresee Pharmaceuticals Co.

o Phase 3

o Clinicaltrials.gov Information

IV PARP Inhibitors

This class of drugs is a type of targeted therapy that inhibits a tumor cellÕs ability to repair itself, causing them to die. The patients with tumors that have evidence of genetic mutations are most likely to benefit from PARP Inhibitor treatment.

PROfound Study

o Study Drug: olaparib (Lynparza)

o Sponsor: AstraZeneca

o Phase 3

o Clinicaltrials.gov Information

Talapro-1

o Study Drug: talazoparib

o Sponsor: Pfizer

o Phase 2

o Clinicaltrials.gov Information

TRITON2

o Study Drug: rucaparib (Rubraca)

o Sponsor: Clovis Oncology

o Phase 2

o PHEN Information

o Clinicaltrials.gov Information

TRITON3

o Study Drug: rucaparib (Rubraca)

o Sponsor: Clovis Oncology

o Phase 3

o PHEN Information

o Clinicaltrials.gov Information  

Galahad

o Study Drug: niraparib (Zejula)

o Sponsor: Janssen Research & Development

o Phase 2

o Clinicaltrials.gov Information

Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)

o Study Drug: olaparib (Lynparza)

o Sponsor: Spanish Oncology Genito-Urinary Group

o Collaborator: AstraZeneca

o Phase 2

o Clinicaltrials.gov Information

 

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

o Study Drug: olaparib (Lynparza)

o Sponsor: M.D. Anderson Cancer Center

o Collaborators: AstraZeneca/Merck

o Phase 2

o Clinicaltrials.gov Information

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

o Study Drug: olaparib (Lynparza)

o Sponsor: Northwestern University

o Collaborator: AstraZeneca

o Phase 2

o Clinicaltrials.gov Information

Olaparib for BRCAness Phenotype in Pancreatic Cancer

o Study Drug: olaparib (Lynparza)

o Sponsor: M.D. Anderson Cancer Center

o Collaborator: AstraZeneca

o Phase 2

o Clinicaltrials.gov Information

V Monoclonal Antibodies

These drugs work by blocking a variety of signals in the body that help to destroy cancer cells or inhibit their ability to grow.

CheckMate 9KD

o Study Drug: nivolumab (Opdivo)

o Sponsor: Bristol-Myers Squibb

o Collaborators: Clovis Oncology, Astellas Pharma

o Phase 2

o Clinicaltrials.gov Information

Phase II Trial of Pembrolizumab (MK-3475) in Subjects With Metastatic Castration-Resistant Prostate Cancer

o Study Drug: pembrolizumab (Keytruda)

o Sponsor: Merck Sharp & Dohme Corp.

o Phase 2

o Clinicaltrials.gov Information

Tremelimumab + Durvalumab Chemotherapy Naive CRPC

o Study Drug: durvalumab (Imfinzi), tremelimumab

o Sponsor: M.D. Anderson Cancer Center

o Collaborator: MedImmune

o Phase 2

o Clinicaltrials.gov Information

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen (IMbassador250)

o Study Drug: atezolizumab (Tecentriq)

o Sponsor: Hoffmann-La Roche

o Phase 3

o Clinicaltrials.gov Information

VI Immunotherapy

This class of drugs stimulates the bodyÕs own immune system to respond to cancerous cells.

PrTK03

o Study Drug: AdV-tk (ProstAtak)

o Sponsor: Advantagene, Inc

o Phase 3

o Clinicaltrials.gov Information

VISION

o Study Drug: 177Lu-PSMA-617

o Sponsor: Endocyte

o Phase 3

o Clinicaltrials.gov Information

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

o Study Drug: AD5-SGE-REIC/Dkk-3

o Sponsor: Momotaro-Gene Inc.

o Phase 2

o Clinicaltrials.gov Information

A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer

o Study Drug: DCVAC/PCa, ONCOS-102

o Sponsor: Sotio a.s.

o Phase 2

o Clinicaltrials.gov Information

VII Molecular Inhibitors

This class of drugs interferes with certain cell signals that prevent cancer cells from growing and helps facilitate their death.

IPATential150

o Study Drug: ipatasertib

o Sponsor: Hoffmann-La Roche

o Phase 3

o PHEN Information

o Clinicaltrials.gov Information

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer

o Study Drug: LY3023414

o Sponsor: Eli Lilly and Company

o Phase 2

o Clinicaltrials.gov Information

A Phase 2 Study of PCM-075 in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

o Study Drug: PCM-075

o Sponsor: Trovagene, Inc.

o Phase 2

o Clinicaltrials.gov Information

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

o Study Drug: TRC253

o Sponsor: Tracon Pharmaceuticals Inc.

o Collaborator: Jansen Pharmaceuticals

o Phase 2

o Clinicaltrials.gov Information

ProSTAR

o Study Drug: CPI-1205

o Sponsor: Constellation Pharmaceuticals

o Phase 2

o Clinicaltrials.gov Information

Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

o Study Drug: CORT125281

o Sponsor: Corcept Therapaeutics.

o Phase 2

o Clinicaltrials.gov Information

Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression

o Study Drug: ribciclib (Kisqali)

o Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson university

o Collaborator: Novartis

o Phase 2

o Clinicaltrials.gov Information

VIII Chemotherapy

This class of drugs specifically interacts with cancer cells in a way that they prevents them from multiplying and promotes their death.

Trial of NanoPac¨ Focal Therapy in Subjects With Prostate Cancer

o Study Drug: NanoPac

o Sponsor: NonOlogy

o Phase 2

o Clinicaltrials.gov Information

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

o Study Drug: cabazitaxel (Jevtana)

o Sponsor: University of California, Davis

o Collaborator: Sanofi

o Phase 2

o Clinicaltrials.gov Information

IX Multiple Drug Interventions

The trials below have multiple drug mechanisms working to battle cancer in different ways.

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

o Study Drugs: abiraterone, prednisone, Radium-223 dichloride, cabazitaxel, carboplatin, enzalutamide

o Sponsor: Icahn School of Medicine at Mount Sinai

o Collaborators: Sanofi/Bayer

o Clinicaltrials.gov Information

PEACE2: A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse (PEACE2)

o Study Drugs: cabazitaxel, Pelvic radiotherapy, ADT.

o Sponsor: Unicancer

o Collaborator: Sanofi

o Phase 3

o Clinicaltrials.gov Information

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

o Study Drugs: ADT+docetaxel+enzalutamide,

o Sponsor: Earle Burgess

o Collaborators: Astellas Pharma/Medivation

o Phase 2

o Clinicaltrials.gov Information

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

o Study Drugs: avelumab (Bavencio) + talazoparib,

o Sponsor: Pfizer

o Phase 2

o Clinicaltrials.gov Information

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

o Study Drugs: cabozantinib + atezolizumab

o Sponsor: Exelis

o Phase 2

o Clinicaltrials.gov Information

PHEN,Inc. © 2018 All rights reserved